Drug Trial Radar · NCT00884221
MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer
Last checked: Nov 20, 2026Latest source record: Apr 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
749
Actual
Start
Jul 2009
Primary completion
Jul 2010
Study completion Jan 2011
Sponsor
- Lead sponsor
- Ferring PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 20, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 21 years, up to 34 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this clinical research trial was to compare the ongoing pregnancy rate between two gonadotrophins for controlled ovarian stimulation (MENOPUR and recombinant follicle-stimulating hormone (FSH)), in cycles where a gonadotrophin-releasing hormone (GnRH) antagonist was used for prevention of premature luteinizing hormone (LH) surge and where a single embryo was transferred at the blastocyst stage.
Conditions
- Infertility
Interventions
Highly purified menotrophinDrug
The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days. NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.
Recombinant FSHDrug
The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days. NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ongoing Pregnancy After One Fresh Embryo Replacement Cycle, Intention-to-treat (ITT) Analysis SetTime frame: 10-11 weeks after embryo transfer at the blastocyst stage
- Ongoing Pregnancy After One Fresh Embryo Replacement Cycle, Per-protocol (PP) Analysis SetTime frame: 10-11 weeks after embryo transfer at the blastocyst stage
Locations
25 sites in 7 countries. Site status is shown where the registry gives one.
ERASME Hospital
Anderlecht, Belgium
UZ Brussel
Brussels, Belgium
UZ Antwerpen
Edegem, Belgium
UZ Gent
Ghent, Belgium
IVF Institute
Pilsen, Czechia
ISCARE IVF a.s.
Prague, Czechia
Pronatal
Prague, Czechia
H:S Rigshospitalet
Copenhagen, Denmark
Amtssygehuset Herlev
Herlev, Denmark
Sygehus Vestsjælland
Holbæk, Denmark
H:S Hvidovre Hospital
Hvidovre, Denmark
KRIOBANK
Bialystok, Poland
nOvum
Warsaw, Poland
IU Dexeus
Barcelona, Spain
GINEFIV, Madrid
Madrid, Spain
IVI Madrid
Madrid, Spain
Ginemed
Seville, Spain
IVI Sevilla
Seville, Spain
IVI Valencia
Valencia, Spain
Fertilitetscentrum AB Gothenburg
Gothenburg, Sweden
IVF-kliniken CURA
Malmö, Sweden
RMC, Malmö
Malmö, Sweden
Hacettepe University
Ankara, Turkey (Türkiye)
American Hospital
Istanbul, Turkey (Türkiye)
Memorial Hospital
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.